IMR Press / FBL / Volume 12 / Issue 11 / DOI: 10.2741/2385

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Abnormal DNA methylation, epigenetics, and prostate cancer
Show Less
1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Brady Urological Institute, Baltimore, MD 21231, USA
Front. Biosci. (Landmark Ed) 2007, 12(11), 4254–4266;
Published: 1 May 2007

Human prostatic carcinogenesis is characterized by the accumulation of both genetic and epigenetic alterations. The epigenetic changes appear earlier and more consistently, and because the DNA sequence remains intact, may be therapeutically reversible. The mechanism(s) by which epigenetic changes appear during the pathogenesis of prostate cancer have not been established. Nonetheless, new methods for the detection of abnormal DNA methylation, a molecular biomarker of epigenetic alterations, are poised to provide clinical tests potentially useful for prostate cancer detection and diagnosis. In addition, new drugs targeting DNA methyltransferases and other enzymes involved in the maintenance of chromatic structure have been introduced into clinical trials for the treatment of advanced prostate cancers. If sufficiently safe strategies for chromatin modulation can be discovered and developed, epigenetic alterations may become rational targets for both prostate cancer prevention and prostate cancer treatment.

DNA methylation
CpG island
DNA methyltransferase
5-meCpG binding domain protein
Back to top